<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00510224</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF055514</org_study_id>
    <nct_id>NCT00510224</nct_id>
  </id_info>
  <brief_title>Sandostatin for Patients With Androgen Independent Prostate Cancer</brief_title>
  <official_title>A Phase II Study of the Somatostatin Analog Sandostatin LAR in Patients With Androgen Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single center Phase II trial of Sandostatin LAR in patients with
      hormone refractory prostate cancer. Patients will receive Sandostatin LAR 30 mg
      intramuscularly every 28 days. Patients will be treated until the time of disease
      progression, unacceptable toxicity or withdrawal of consent. The study will require 27
      evaluable patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      To evaluate changes in prostate specific antigen (PSA) in patients with androgen independent
      prostate cancer who are treated with Sandostatin LAR.

      Secondary Objective:

      To evaluate the effects of Sandostatin LAR on circulating levels of Insulin Growth Factor-1
      and Insulin Growth Factor Binding Protein 1.

      To evaluate the safety of Sandostatin LAR in this patient population. To evaluate the pre
      versus post treatment mitogenic effects of serum derived from subjects with prostate cancer
      compared to pretreatment serum.

      Patients with androgen independent prostate cancer who do not have bone or visceral
      metastases are selected for this trial because they are a patient population that is likely
      to have no symptoms from the disease or rapid progression that would suggest the need for
      chemotherapy. Additionally, given the preclinical data suggesting that IGF-1 expression and
      signaling occurs concomitantly with the onset of androgen independent growth, it is felt that
      testing in the &quot;early&quot; androgen independent state is warranted. This trial is consistent with
      overall goal to develop IGF-1 targeted therapies in patients with disease progression and a
      lower disease burden.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped at interim analyses phase due to lack of efficacy
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants with a PSA decline of at least 50% from Baseline during the first 3 cycles of therapy, confirmed by a second measurement at least 2 weeks later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-post Percent Change in Circulating Levels of IGF-1 and IGF-Binding Protein 1.</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Serum was batched and IGF and IGFBP levels were assayed at one time at the end of the study using an enzyme-linked immunoabsorbent assay (ELISA) method by Diagnostic Systems Laboratories (Webster, TX).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 4-5 Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre Versus Post Treatment Mitogenic Effects.</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sandostatin</intervention_name>
    <description>Sandostatin 30mg intramuscular every 28 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate.

          -  Biochemical disease progression following androgen deprivation and therapy with at
             least one antiandrogen defined as three rises in PSA with PSA determinations at least
             4 weeks apart and each PSA value &gt; 0.2 ng/ml.

          -  Four weeks since prior therapy with Flutamide.

          -  Six weeks since prior therapy with Bicalutamide or Nilutamide.

          -  Current PSA &gt; 5 ng/ml.

          -  Testosterone &lt;50 ng/dL.

          -  SGPT (ALT) &lt; 1.5 times upper limit of normal.

          -  Fasting blood glucose &gt; 60 mg/dL.

          -  ECOG performance status 0, 1 or 2.

          -  No visceral or bony metastatic disease (Lymph node only metastases are allowed).

          -  No prior chemotherapy for prostate cancer.

          -  No current treatment with insulin or an oral hypoglycemic.

          -  No history of treatment with octreotide analogs for prostate cancer.

          -  No NYHA Class 3 or 4 cardiac status.

        Exclusion Criteria:

          -  Diabetes Mellitus requiring medical therapy and/or that which is not controlled by
             dietary means (HbA1C&lt;6.0).

          -  A history of gallstones that has been clinically significant. Patients who have
             undergone cholecystectomy are eligible.

          -  Other concomitant medical or psychiatric condition which would make it undesirable, in
             the physician's opinion, for the patient to participate in the protocol or would
             jeopardize compliance with the protocol requirements.

          -  Prior treatment with chemotherapy for prostate cancer.

          -  No current treatment with Saw Palmetto, or Proscar. Patients must be off these
             medicines for more than 4 weeks.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Ryan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug;30(4):408-14. doi: 10.1016/j.urolonc.2010.06.014. Epub 2010 Oct 2.</citation>
    <PMID>20884247</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2007</study_first_submitted>
  <study_first_submitted_qc>July 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2007</study_first_posted>
  <results_first_submitted>October 17, 2013</results_first_submitted>
  <results_first_submitted_qc>October 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2013</results_first_posted>
  <last_update_submitted>October 17, 2013</last_update_submitted>
  <last_update_submitted_qc>October 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Men with prostate adenocarcinoma that had progressed despite androgen deprivation therapy were recruited for participation at one U.S. clinical site (UCSF)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Octreotide Acetate</title>
          <description>Octreotide acetate 30mg intramuscular every 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Octreotide Acetate</title>
          <description>Octreotide acetate 30mg intramuscular every 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" lower_limit="63" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary therapy</title>
          <description>Type of therapy prior to study enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Prostatectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiation Therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androgen Deprivation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median PSA</title>
          <description>PSA was measured by chemiluminescent immunoassay on the Immulite 2000 analyzer (Siemens Healthcare Diagnostics, Deerfield, IL)</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.2" lower_limit="5.4" upper_limit="342.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score</title>
          <description>A Gleason score is assigned by a pathologist based on the sum of two numbers: the first number is the grade of the most common tumor pattern, the second number is the grade of the second most common pattern. For example, if the most common tumor pattern was grade 3, but some cells were found to be grade 4, the Gleason Score would be 3+4 = 7. The Gleason Score ranges from 2 to 10, with 10 having the worst prognosis.</description>
          <units>Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>gm/dl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" lower_limit="9.5" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PSA Response</title>
        <description>Number of participants with a PSA decline of at least 50% from Baseline during the first 3 cycles of therapy, confirmed by a second measurement at least 2 weeks later.</description>
        <time_frame>12 weeks</time_frame>
        <population>n=27 was determined to be sufficient to test for a 20% PSA response proportion compared with a null hypothesis of 5%. A two-stage design was employed to carry out an interim analysis for efficacy. As no patient showed a PSA decline among the first 13 accrued after 3 cycles (the first evaluation of PSA response), accrual was discontinued</population>
        <group_list>
          <group group_id="O1">
            <title>Octreotide Acetate</title>
            <description>Octreotide acetate 30mg intramuscular every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Response</title>
          <description>Number of participants with a PSA decline of at least 50% from Baseline during the first 3 cycles of therapy, confirmed by a second measurement at least 2 weeks later.</description>
          <population>n=27 was determined to be sufficient to test for a 20% PSA response proportion compared with a null hypothesis of 5%. A two-stage design was employed to carry out an interim analysis for efficacy. As no patient showed a PSA decline among the first 13 accrued after 3 cycles (the first evaluation of PSA response), accrual was discontinued</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-post Percent Change in Circulating Levels of IGF-1 and IGF-Binding Protein 1.</title>
        <description>Serum was batched and IGF and IGFBP levels were assayed at one time at the end of the study using an enzyme-linked immunoabsorbent assay (ELISA) method by Diagnostic Systems Laboratories (Webster, TX).</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octreotide Acetate</title>
            <description>Octreotide acetate 30mg intramuscular every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-post Percent Change in Circulating Levels of IGF-1 and IGF-Binding Protein 1.</title>
          <description>Serum was batched and IGF and IGFBP levels were assayed at one time at the end of the study using an enzyme-linked immunoabsorbent assay (ELISA) method by Diagnostic Systems Laboratories (Webster, TX).</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGF-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.5" lower_limit="-57.4" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" lower_limit="-45.1" upper_limit="589.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade 4-5 Adverse Events</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octreotide Acetate</title>
            <description>Octreotide acetate 30mg intramuscular every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 4-5 Adverse Events</title>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre Versus Post Treatment Mitogenic Effects.</title>
        <time_frame>12 Weeks</time_frame>
        <population>The trial was closed for futility after no PSA responses were observed among the first 13 patients, and this analysis was not performed</population>
        <group_list>
          <group group_id="O1">
            <title>Octreotide Acetate</title>
            <description>Octreotide acetate 30mg intramuscular every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pre Versus Post Treatment Mitogenic Effects.</title>
          <population>The trial was closed for futility after no PSA responses were observed among the first 13 patients, and this analysis was not performed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>While on study therapy (9-51 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Octreotide Acetate</title>
          <description>Octreotide acetate 30mg intramuscular every 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated INR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Scleral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles J. Ryan, MD</name_or_title>
      <organization>UCSF</organization>
      <phone>415-353-9279</phone>
      <email>ryanc@medicine.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

